0001104659-26-049508
SEC filingNervGen Pharma Corp. appointed Keith Vendola, MD, MBA, as CFO effective April 27, 2026, and disclosed results from its April 23, 2026 annual shareholder meeting approving directors, auditors, equity plans, and articles amendments.
The appointment of Keith Vendola as CFO strengthens NervGen's leadership with his extensive biopharma finance experience from roles at Wugen, IO Biotech, Rezolute, and Coherus, plus investment banking at BofA and JPMorgan. This supports the company's clinical-stage growth, particularly NVG-291 development for spinal cord injury. The AGM results show strong shareholder alignment, with near-unanimous approvals for governance changes including Nasdaq-compliant quorum increase, auditor re-appointment, and equity incentive plans to attract talent. Director elections reflect continued board stability, though higher withheld votes for Krista L. McKerracher (13.22%) may indicate specific concerns.